– Completed Scientific Advice meeting with UK MHRA to support Phase 1/2a trial of CYB003 planned for mid-2022 – – Company to host conference call at 8:30am EST today – TORONTO–( BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics”, today reported unaudited financial results for its…


Previous articlePT292 – Sam Gandy – Vital Psychedelic Conversations
Next articlePsychedelic Bulletin: Mindstate Design Labs Leaves Stealth Mode; No Synthetic Psilocybin in Oregon?